INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, published by Lippincott Williams & Wilkins, is a premier academic journal dedicated to the intricate field of gynecological pathology, serving a critical role in advancing the understanding of diseases related to women's reproductive health. Since its inception in 1982, this journal has established itself as a key resource for researchers, clinicians, and students, with a current impact factor that reflects its esteemed reputation; it is ranked in the Q2 category for both Obstetrics and Gynecology, as well as Pathology and Forensic Medicine, signifying its prominence in academic circles. The journal's scope encompasses a wide array of topics, including histopathological findings, diagnostic methodologies, and evolving therapeutic strategies, all pivotal to enhancing patient care. With a steadfast commitment to disseminating high-quality research until the projected year of 2024, the INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY is an essential read for those looking to stay abreast of the latest developments in this vital area of medical science.

ENDOCRINE PATHOLOGY is a premier journal published by HUMANA PRESS INC, dedicated to advancing the understanding of endocrine disorders through innovative research and clinical practices. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories such as Endocrinology, Diabetes and Metabolism, as well as Pathology and Forensic Medicine, this journal serves as a pivotal resource for researchers and professionals in the field. The journal covers a broad spectrum of topics related to endocrine pathology, providing insights into mechanisms, diagnostics, and therapeutics that inform both clinical and laboratory practices. Although it does not offer open access, its rigorous peer-review process ensures the dissemination of high-quality, impactful research that shapes clinical strategies and enhances patient care. With distribution spanning from its inception in 1990 to 2024, ENDOCRINE PATHOLOGY stands at the forefront of endocrine research, making it an essential read for anyone involved in the study and treatment of endocrine disorders.

SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

PATHOLOGY INTERNATIONAL, published by WILEY, stands as a distinguished journal in the field of pathology and forensic medicine, serving as an essential resource for researchers, clinicians, and students alike. With its ISSN 1320-5463 and E-ISSN 1440-1827, PATHOLOGY INTERNATIONAL has established itself since its inception in 1951, navigating through an evolving landscape in medical science with insights and breakthroughs up to 2024. It holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pathology and Forensic Medicine categories, indicating its robust influence and quality within these fields, as evidenced by its placement in the 70th percentile of Scopus rankings. While currently not an open-access journal, it provides access options that ensure valuable research remains available to the academic community. PATHOLOGY INTERNATIONAL commits to advancing the discipline through pioneering research articles, comprehensive reviews, and expert opinions that push the boundaries of understanding in pathology, thereby supporting the enhancement of diagnostic and therapeutic practices.

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.